

Supplementary Information

ESI-Q-TOF-MS/MS fragmentations of compounds 1-5	Figure S1
The ^1H NMR (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamide A (1)	Figure S2
The ^{13}C NMR (150 MHz, $\text{MeOH-}d_4$) spectrum of apliamide A (1)	Figure S3
The COSY (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamide A (1)	Figure S4
The gHSQC (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamide A (1)	Figure S5
The gHMBC (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamide A (1)	Figure S6
The ^1H NMR (400 MHz, $\text{MeOH-}d_4$) spectrum of apliamide B (2)	Figure S7
The ^{13}C NMR (100 MHz, $\text{MeOH-}d_4$) spectrum of apliamide B (2)	Figure S8
The COSY (400 MHz, $\text{MeOH-}d_4$) spectrum of apliamide B (2)	Figure S9
The gHSQC (400 MHz, $\text{MeOH-}d_4$) spectrum of apliamide B (2)	Figure S10
The gHMBC (400 MHz, $\text{MeOH-}d_4$) spectrum of apliamide B (2)	Figure S11
The ^1H NMR (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamide C (3)	Figure S12
The ^{13}C NMR (150 MHz, $\text{MeOH-}d_4$) spectrum of apliamide C (3)	Figure S13
The COSY (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamide C (3)	Figure S14
The gHSQC (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamide C (3)	Figure S15
The gHMBC (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamide C (3)	Figure S16
The ^1H NMR (600 MHz, CDCl_3) spectrum of apliamide D (4)	Figure S17
The ^{13}C NMR (150 MHz, CDCl_3) spectrum of apliamide D (4)	Figure S18
The COSY (600 MHz, CDCl_3) spectrum of apliamide D (4)	Figure S19
The gHSQC (600 MHz, CDCl_3) spectrum of apliamide D (4)	Figure S20
The gHMBC (600 MHz, CDCl_3) spectrum of apliamide D (4)	Figure S21
The ^1H NMR (500 MHz, $\text{MeOH-}d_4$) spectrum of apliamide E (5)	Figure S22
The ^{13}C NMR (125 MHz, $\text{MeOH-}d_4$) spectrum of apliamide E (5)	Figure S23
The COSY (500 MHz, $\text{MeOH-}d_4$) spectrum of apliamide E (5)	Figure S24
The gHSQC (500 MHz, $\text{MeOH-}d_4$) spectrum of apliamide E (5)	Figure S25
The gHMBC (500 MHz, $\text{MeOH-}d_4$) spectrum of apliamide E (5)	Figure S26
The ^1H NMR (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamine A (6)	Figure S27
The ^{13}C NMR (150 MHz, $\text{MeOH-}d_4$) spectrum of apliamine A (6)	Figure S28
The COSY (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamine A (6)	Figure S29
The gHSQC (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamine A (6)	Figure S30
The gHMBC (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamine A (6)	Figure S31
The result of antibacterial and enzyme inhibition test.	Table S1




Figure S1. ESI-Q-TOF-MS/MS fragmentations of compounds 1–5.




Figure S2. The ¹H NMR (600 MHz, MeOH-*d*₄) spectrum of apilamide A (1).




Figure S3. The ^{13}C NMR (150 MHz, $\text{MeOH-}d_4$) spectrum of apliamide A (1).




Figure S4. The COSY (600 MHz, MeOH-*d*₄) spectrum of apliamide A (**1**)




Figure S5. The gHSQC (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamide A (**1**).




Figure S6. The gHMBC (600 MHz, MeOH-*d*₄) spectrum of apliamide A (1).




Figure S7. The ¹H NMR (400 MHz, MeOH-*d*₄) spectrum of apilamide B (2).




Figure S8. The ^{13}C NMR (100 MHz, $\text{MeOH-}d_4$) spectrum of apliamide B (**2**).




Figure S9. The COSY (400 MHz, MeOH-*d*₄) spectrum of apliamide B (2).




Figure S10. The gHSQC (400 MHz, MeOH- d_4) spectrum of apliamide B (2).




Figure S11. The gHMBC (400 MHz, MeOH-*d*₄) spectrum of apliamide B (2).




Figure S12. The ¹H NMR (600 MHz, MeOH-*d*₄) spectrum of apliamide C (3).




Figure S13. The ^{13}C NMR (150 MHz, $\text{MeOH}-d_4$) spectrum of apliamide C (**3**).




Figure S14. The COSY (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamide C (3).




Figure S15. The gHSQC (600 MHz, MeOH-*d*₄) spectrum of apliamide C (**3**).




Figure S16. The gHMBC (600 MHz, MeOH-*d*₄) spectrum of apliamide C (3).




Figure S17. The ¹H NMR (600 MHz, CDCl₃) spectrum of apliamide D (4).




Figure S18. The ^{13}C NMR (150 MHz, CDCl_3) spectrum of apliamide D (4).




Figure S19. The COSY (600 MHz, CDCl₃) spectrum of apliamide D (**4**).




Figure S20. The gHSQC (600 MHz, CDCl₃) spectrum of apliamide D (4).




Figure S21. The gHMBC (600 MHz, CDCl₃) spectrum of apiamide D (4).




Figure S22. The ¹H NMR (600 MHz, MeOH-*d*₄) spectrum of apliamide E (5).




Figure S23. The ^{13}C NMR (150 MHz, $\text{MeOH-}d_4$) spectrum of apliamide E (**5**).




Figure S24. The COSY (600 MHz, MeOH-*d*₄) spectrum of apliamide E (**5**).




Figure S25. The gHSQC (600 MHz, MeOH-*d*₄) spectrum of apliamide E (**5**).




Figure S26. The gHMBC (600 MHz, MeOH-*d*₄) spectrum of apliamide E (**5**).




Figure S27. The ^1H NMR (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamine A (6).




Figure S28. The ^{13}C NMR (150 MHz, $\text{MeOH-}d_4$) spectrum of apliamine A (6).




Figure S29. The COSY (600 MHz, $\text{MeOH-}d_4$) spectrum of apliamine A (6).




Figure S30. The gHSQC (600 MHz, MeOH- d_4) spectrum of apliamine A (6).




Figure S31. The gHMBC (600 MHz, MeOH-*d*₄) spectrum of apliamine A (6).

Table S1. The result of antibacterial and enzyme inhibition test ^a.

Compound	MIC (µg/mL)						IC ₅₀ (µM)	
	Gram(+) bacterium			Gram(−) Bacterium			Srt A	ICL
	A	B	C	D	E	F		
1	>100	>100	>100	>100	>100	>100	>300	>100
2	>100	>100	>100	>100	>100	>100	>300	>100
3	>100	>100	>100	>100	>100	>100	>300	>100
4	>100	>100	>100	>100	>100	>100	>300	>100
5	>100	>100	>100	>100	>100	>100	>300	>100
6	>100	>100	>100	>100	>100	>100	>300	>100
Ampicillin	0.4	0.4	0.4	0.4	0.8	6.3		
pHMB ^b							109.2	
3-NP ^c								16.2

^a A: *Staphylococcus aureus* (ATCC 6538p), B: *Bacillus subtilis* (ATCC 6633), C: *Micrococcus luteus* (IFO 12708), D: *Salmonella typhimurium* (ATCC 14028), E: *Proteus vulgaris* (ATCC 3851), F: *Escherichia coli* (ATCC 35270); ^b para-Hydroxymercuribenzoic acid; ^c 3-Nitropropionic acid.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).